Clin Exp Pediatr:韩国人群10年哮喘、过敏性鼻炎和过敏性皮肤炎的趋势和患病率

2020-02-24 AlexYang MedSci原创

考虑到韩国过敏性疾病和哮喘的年龄分层趋势,目前仍旧存在很多重要的问题。最近,有研究人员鉴定了2008年到2017年评估的10年哮喘、过敏性鼻炎和过敏性皮肤炎患病率情况。研究是一个全国的代表性调查,为期10年(2008年到2017年),调查的是代表性的韩国样本群体(n=85006),其中包括了2131名婴幼儿,4352名学龄前儿童,12919名学龄儿童,44200名成年人和21404名老年人。研究发

考虑到韩国过敏性疾病和哮喘的年龄分层趋势,目前仍旧存在很多重要的问题。最近,有研究人员鉴定了2008年到2017年评估的10年哮喘、过敏性鼻炎和过敏性皮肤炎患病率情况。

研究是一个全国的代表性调查,为期10年(2008年到2017年),调查的是代表性的韩国样本群体(n=85006),其中包括了2131名婴幼儿,4352名学龄前儿童,12919名学龄儿童,44200名成年人和21404名老年人。研究发现,在2016年到2017年的群体中,哮喘的患病率在婴幼儿中为0.9%,学龄前儿童为2.3%,学龄儿童中为4.1%,成年人中为2.3%,老年人中为4.1%。过敏性鼻炎的患病率在婴幼儿中为9.0%,学龄前儿童为20.2%,学龄儿童中为27.6%,成年人中为17.1%,老年人中为6.9%。过敏性皮肤炎在婴幼儿中为5.9%,学龄前儿童为11.3%,学龄儿童中为14.6%,成年人中为3.9%,老年人中为1.6%。10年趋势阐释了哮喘患病率在婴幼儿、学龄前儿童和老年人中显著减少,且过敏性皮肤炎患病率在婴幼儿和学龄前儿童中也显著减少(p<0.05)。更多的是,10年趋势阐释了过敏性鼻炎在学龄儿童、成年人和老年人中显著减少,过敏性皮肤炎在学龄儿童和老年人中也显著减少(p<0.05)。

最后,研究人员指出,他们的结果改善了对过敏性疾病年龄分层流行病学的认知,表明了需要定制赫尔精准的策略来预防不同年龄段的过敏性疾病。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639368, encodeId=99e316393680c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 02 01:16:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728317, encodeId=8bd31e2831776, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Sep 11 01:16:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047229, encodeId=b035204e229cb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Apr 25 18:16:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379860, encodeId=a9093e9860d6, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Feb 28 08:46:27 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250669, encodeId=753312506694e, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334882, encodeId=d6dc1334882da, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466523, encodeId=b377146652314, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639368, encodeId=99e316393680c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 02 01:16:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728317, encodeId=8bd31e2831776, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Sep 11 01:16:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047229, encodeId=b035204e229cb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Apr 25 18:16:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379860, encodeId=a9093e9860d6, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Feb 28 08:46:27 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250669, encodeId=753312506694e, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334882, encodeId=d6dc1334882da, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466523, encodeId=b377146652314, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]
    2020-09-11 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639368, encodeId=99e316393680c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 02 01:16:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728317, encodeId=8bd31e2831776, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Sep 11 01:16:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047229, encodeId=b035204e229cb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Apr 25 18:16:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379860, encodeId=a9093e9860d6, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Feb 28 08:46:27 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250669, encodeId=753312506694e, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334882, encodeId=d6dc1334882da, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466523, encodeId=b377146652314, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1639368, encodeId=99e316393680c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 02 01:16:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728317, encodeId=8bd31e2831776, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Sep 11 01:16:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047229, encodeId=b035204e229cb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Apr 25 18:16:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379860, encodeId=a9093e9860d6, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Feb 28 08:46:27 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250669, encodeId=753312506694e, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334882, encodeId=d6dc1334882da, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466523, encodeId=b377146652314, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]
    2020-02-28 一天没事干

    很好的学习机会

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1639368, encodeId=99e316393680c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 02 01:16:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728317, encodeId=8bd31e2831776, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Sep 11 01:16:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047229, encodeId=b035204e229cb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Apr 25 18:16:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379860, encodeId=a9093e9860d6, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Feb 28 08:46:27 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250669, encodeId=753312506694e, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334882, encodeId=d6dc1334882da, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466523, encodeId=b377146652314, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1639368, encodeId=99e316393680c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 02 01:16:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728317, encodeId=8bd31e2831776, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Sep 11 01:16:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047229, encodeId=b035204e229cb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Apr 25 18:16:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379860, encodeId=a9093e9860d6, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Feb 28 08:46:27 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250669, encodeId=753312506694e, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334882, encodeId=d6dc1334882da, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466523, encodeId=b377146652314, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1639368, encodeId=99e316393680c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Aug 02 01:16:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728317, encodeId=8bd31e2831776, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Sep 11 01:16:00 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047229, encodeId=b035204e229cb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Apr 25 18:16:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379860, encodeId=a9093e9860d6, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Feb 28 08:46:27 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250669, encodeId=753312506694e, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334882, encodeId=d6dc1334882da, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466523, encodeId=b377146652314, content=<a href='/topic/show?id=dc6a9404edd' target=_blank style='color:#2F92EE;'>#过敏性皮肤炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94047, encryptionId=dc6a9404edd, topicName=过敏性皮肤炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffad6824521, createdName=ssnine, createdTime=Wed Feb 26 13:16:00 CST 2020, time=2020-02-26, status=1, ipAttribution=)]

相关资讯

Adv Med Sci:药物治疗对永久过敏性鼻炎患者的鼻呼出一氧化氮(NO)影响研究

最近,有研究人员评估了鼻一氧化氮(NO)在治疗永久过敏性鼻炎(PER)患者中的作用。研究是一个随机和比较性的研究。研究的受试者包括对照(健康对照)和PER患者。研究人员搜集了所有的临床、功能和生物学数据进行分析,并电致发光设备测量了呼出NO组分(FENO)。PER患者随机的进行抗组胺结合白三烯素阻断剂(LRA)治疗或者单独鼻内类固醇治疗(INS)。研究持续的时间为2年,包括了501名受试者:234

Int Arch Allergy Immunol:过敏性鼻炎中治疗前视觉模拟量表能够预测治疗结果么?

剂治疗,共进行28天。研究发现,治疗前VAS评分与治疗前TNSSs(总鼻症状得分)和NMCCTs(鼻粘膜清除时间)呈现正相关关系(分别为ρ=0.66, p<0.001和r=0.44, p<0.001)。在治疗后,治疗前VAS评分与治疗后GSCs(整体症状控制)呈现负相关关系(r=-0.53, p<0.001)。TNSSs和NMCCTs的最小临床重要差异值(MCID)分别为3.19

Int Arch Allergy Immunol:常年过敏原免疫疗法在过敏性鼻炎患者中疗效研究

在现实生活背景下,关于比较过敏原免疫疗法(AIT)与药物治疗在常年过敏性鼻炎(AR)疗效的研究很少。最近,有研究人员在患有或者不患有哮喘的AR患者中,比较了AIT和药物治疗对症状的控制和生活质量(QOL)的效果情况。研究包括了250名患有或者不患有哮喘的AR患者,并分配到免疫治疗组(AIT加药物治疗)和对照组(只有药物治疗)。研究发现,AIT组中AR症状具有临床改善,而只进行标准的药物治疗组中对鼻

Adv Med Sci:哮喘和过敏性鼻炎儿童上呼吸道鼻一氧化氮研究

最近,有研究人员在患有呼吸道疾病的儿科患者中比较了鼻一氧化氮(nNO)水平。研究包括了179名年龄在7-15岁的患有哮喘、过敏性鼻炎或者哮喘和过敏性鼻炎的患者,研究还包括了从当地过敏诊所招募的健康对照。研究人员评估了nNO水平与患者的临床参数之间的关系。研究发现,nNO水平在过敏性鼻炎患者(2316.3±442.33 ppb, p<0.001)中和哮喘和过敏性鼻炎(2399.9±446.73

Cytokine:过敏性鼻炎中IL-36α有助于增强辅助性17型T细胞的响应

辅助性T-17型(Th17)细胞亚型属于CD4+ T细胞系,且最近研究证明了其与AR的病理生理具有紧密的联系。有报道表明白介素-36(IL-36)能够促进Th17细胞因子在牛皮藓中表达上调。最近,有研究人员在过敏性鼻炎中调查了IL-36家族细胞因子对Th17炎症的调控情况。研究包括了21名AR患者和20名健康对照。研究人员检测和比较了AR患者和对照的受试者IL-36家族的血清蛋白水平和mRNA水平

Int Forum Allergy Rhinol:过敏性鼻炎中TSLP和IL-33/ST2的协同作用以及组织缺氧作用研究

世界卫生组织(WHO)已经注明了过敏性疾病是21世纪的一个主要的健康问题。过敏性鼻炎(AR)是I型过敏性疾病,并通过鼻粘膜和免疫系统异常来进行鉴定。AR可以由各种炎症细胞来介导,并且具有细胞因子分泌改变的特征。胸腺基质淋巴生成素(TSLP)和白介素-33/刺激表达基因2 (IL-33/ST2)信号通路在许多炎症细胞响应和过敏性反应中具有重要的作用。在许多疾病中均报道了上述2个途径的互作关系。组织缺